Curevo Vaccine Names Guy De La Rosa Chief Medical Officer

Curevo Vaccine, a privately held clinical-stage biotechnology company dedicated to reducing the burden of infectious disease by developing safe and highly effective vaccines, announced Guy De La Rosa has joined the company as its new chief medical officer.

“The Curevo team is excited to welcome Dr. De La Rosa to the company,” said George Simeon, Curevo’s CEO. “Guy, with his 20-plus years of experience directing clinical trials in the infectious disease space, will immediately bring a positive impact to our CRV-101 vaccine programs against shingles and chickenpox.”

“During the course of several conversations with George and many of the team members at Curevo, it became clear to me this was a company I wanted to join,” said De La Rosa, “It’s an exceptionally productive team developing a very promising vaccine, and I’m excited to work with all of them to bring CRV-101 into use as quickly as we can.”

De La Rosa brings more than 20 years of clinical experience to the Curevo team, previously directing successful development programs across multiple areas in the field of infectious disease. Prior to joining Curevo, De La Rosa worked for Enanta Pharmaceuticals, where he served in roles of increasing seniority, culminating as executive medical director for infectious diseases, leading the clinical development for several assets for RSV, SARS-CoV-2, and HBV.

Before to his tenure at Enanta, De La Rosa held positions with Abbott, Janssen, and Takeda Pharmaceuticals where he led the development of assets for HIV, HCV, RSV, and the Dengue Tetravalent Vaccine program.